CHRONIC TRANSPLANT REJECTION: PROBLEMS, DISCOVERIES, SOLUTIONS

dc.contributor.authorAulds-Stier, Mitchell
dc.contributor.authorSu, Eric
dc.contributor.authorSaltagi, Mohamad
dc.contributor.authorKhan, Karim
dc.contributor.authorWard, Richard
dc.contributor.authorJohnson, Raymond
dc.date.accessioned2016-01-19T19:51:25Z
dc.date.available2016-01-19T19:51:25Z
dc.date.issued2012-04-13
dc.descriptionposter abstracten_US
dc.description.abstractOrgan transplantation has become an increasingly important remedy in helping extend the lives of patients with organ failures or deficien-cies. Although the survival rates of organ recipients have dramatically increased in the short term (1-5 years), long-term (5+ years) survival rates have not improved significantly. Additionally, increasingly un-healthy lifestyles have contributed to a dramatic increase in the need for organ transplants, while organ supply has only slightly increased, resulting in a constantly increasing gap between organ demand and organ supply. Dr. Raymond Johnson, an IU Health Physician, discov-ered a new T cell subset that is resistant to medications routinely used to prevent transplant rejection. This discovery is important because it can be used to develop mechanism-specific diagnostic blood tests for chronic rejection and, potentially, new drugs to treat chronic trans-plant rejection. However, innovations developed in faculty labs often face multiple hurdles in reaching the market place. As participants in the Innovation-to-Technology Central (ITEC) program, our unique multidisciplinary team of students investigated Dr. Raymond Johnson’s discovery by conducting literature research and expert interviews on organ transplantation and rejection and pharmaceutical drugs used in preventing acute transplant rejection. Through our research and our interviews, we were able to further document the dire need for meth-ods for increasing survival rates of transplanted organs. Most im-portantly, we have conducted preliminary market research and devel-oped several commercialization strategy recommendations based on comparable innovation analysis and precedent biotechnology start-up strategies. We anticipate that our research will provide Dr. Johnson with new information and perspectives to help seek venture capitalists to invest in his research, which holds the promise to change the lives of thousands of transplant recipients each year. Funding provided by IUPUI’s Innovation-to-Enterprise Central (ITEC).en_US
dc.identifier.citationMitchell Aulds-Stier, Eric Su, Mohamad Saltagi, Karim Khan, Richard Ward, and Raymond Johnson. (2012, April 13). CHRONIC TRANSPLANT REJECTION: PROBLEMS, DISCOVERIES, SOLUTIONS. Poster session presented at IUPUI Research Day 2012, Indianapolis, Indiana.en_US
dc.identifier.urihttps://hdl.handle.net/1805/8111
dc.language.isoen_USen_US
dc.publisherOffice of the Vice Chancellor for Researchen_US
dc.subjectOrgan transplantationen_US
dc.subjectorgan failuresen_US
dc.subjectsurvival ratesen_US
dc.subjecttransplant rejectionen_US
dc.titleCHRONIC TRANSPLANT REJECTION: PROBLEMS, DISCOVERIES, SOLUTIONSen_US
dc.typePosteren_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Su-Chronic.pdf
Size:
12.55 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: